Amarin Corporation plc · NASDAQ:AMRN
Amarin — Q3 2024 Earnings Presentation
13 slides from Amarin's earnings presentation, Oct 30, 2024
Slide 1: Third Quarter 2024 Business Update & Financial Results Conference Call
Third Quarter 2024 Business Update & Financial Results Conference Call October 30, 2024
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA®(VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, rese
Slide 3: Today's Agenda
Today’s Agenda STATE OF THE BUSINESS: AN UPDATE 01 Aaron Berg, President & CEO THIRD QUARTER 2024 FINANCIAL RESULTS 02 Peter Fishman, Vice President, Global Controller CLOSING REMARKS & Q&A 03 Aaron Berg, President & CEO
Slide 4: State of the Business: An Update
01 STATE OF THE BUSINESS: AN UPDATE Aaron Berg President & CEO
Slide 5: Key Global Commercial Highlights
KEY GLOBAL COMMERCIAL HIGHLIGHTS VAZKEPA / VASCEPA HAS SIGNIFICANT VALUE GLOBALLY Large Global Burden of Disease and Need for CV Risk Reduction Proven Efficacy and Safety, Strong KOL and Scientific Guideline Support US Success of >200K Prescribers, >25M Prescriptions and Cumulative Sales of ~$3.2Bn
Slide 6: Year-to-Date 2024 Operational Highlights & Ongoing Priorities
BUSINESS UPDATE YEAR-TO-DATE 2024 OPERATIONAL HIGHLIGHTS & ONGOING PRIORITIES AMARIN CONTINUES TO MAKE PROGRESS ACROSS ALL ASPECTS OF OUR BUSINESS OPERATIONS AND ARE EXECUTING AS PLANNED AGAINST OUR STRATEGIC PRIORITIES EUROPE REST OF WORLD PRIORITIES: PRIORITIES: • Accelerate revenue growth in Euro
Slide 7: Third Quarter 2024 Financial Results
02 THIRD QUARTER 2024 FINANCIAL RESULTS Peter Fishman Vice President, Global Controller
Slide 8: Q3 2024 P&L Highlights
Q3 2024 P&L HIGHLIGHTS Q3 ’24 Total Revenue of $42.3M Q3 ‘24 Operating Expenses • USA Revenue: $30.6 million; ~30% reduction vs. Q2 2024 due to • ~$10M reduction in Total Operating Expenses lower NSP and volume Q3 ‘24 vs. Q3 ‘23 • European Revenue: $4.3 million; ~19% increase vs. Q2 2024 driven • Co
Slide 9: Continued Focus on Maintaining Cash Position to Fund Ongoing Operations
FINANCIAL RESULTS CONTINUED FOCUS ON MAINTAINING CASH POSITION TO FUND ONGOING OPERATIONS; EXEMPLIFIES COMPANY’S STRONG CAPITAL STRUCTURE Strong Cash Position; Nine Consecutive Quarters of Positive/Neutral Cash Balance $313M $321M $321M Third Quarter 2024 $306M $311M $305M $308M $307M $306M • Cash B
Slide 10: Closing Remarks & Q&A
03 CLOSING REMARKS & Q&A Aaron Berg President & CEO
Slide 11: Q3 2024 Recap
Q3 2024 Q3 2024 RECAP Balance sheet provides foundation to support ongoing business operations Europe and RoW, which symbolize the dual pronged global expansion strategy for and execution of expansion plans VASCEPA/VAZKEPA, continue to evolve and build momentum, representing sources of potential lon
Slide 12: Q&A
Q&A
Slide 13: Thank You
Vascepa Vazkepa (icosapent ethyl) (icosapent ethyl) THANK YOU